POAI - Earnings call transcript Q1 2018 | Predictive Oncology Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, everyone, and welcome to the Precision Therapeutics Q1 2018 Business Update Conference Call. Today’s call is being recorded. At this time I would like to turn the call over to Todd Fromer. Please go ahead.

Todd Fromer

Thank you all for participating in today's call to discuss Precision Therapeutics financial results for the first fiscal quarter of 2018.

Dr. are today me Joining Business Carl Schwartz, Chief Executive Therapeutics; Myers, Head of of Executive Officer of Officer of Gabriel, Financial Richard Chief Corporation Precision of Precision; TumorGenesis. Helomics Bob and Chief Development Gerry Officer Vardzel, a Precision its first release today financial Earlier news XXXX results. announcing issued Therapeutics quarter

the news If to distribution email the this if company’s at would release visit www.precisiontherapeutics.com. website have you received like you company's list, or not to added please be

its comments future made may turn XX-K, would over factors management the Helomics to floor I we Forms Carl or Precision events to forward-looking that company's specific identifies I yours. with Schwartz. cause you to Carl, the call statements to Before further, review Therapeutics encourage materially this nothing like by results would filings during limitation, caution from the described will that regarding begin, differ conference the which like results statements. call and including forward-looking those and contain in Securities I Commission, Dr. is the operations actual Corporation. without and of Exchange to the With

Carl Schwartz

first has much. Thank to XXXX who it for I joined call. quarter today's us and And everyone earnings today welcome appreciate you very

subsidiary. more Richard you and Precision a Division, into been Gabriel before before plans Corporation in an I'm across quarter Helomics. provide have update sales financial made progress are pleased our both for on results start the opening recent strategic Bob an will of our have few Vardzel, meaningful with over only by it's from at before CFO recap making Oncology achievements. last CEO I'll to to Gerry Although more discuss opportunity Oncology Myers, we progress, recent call our goes on detail Then in and our progress developments since weeks call the provide to Precision call discussing to Q&A. on Medical's the we turning detail in our the then update these Skyline recent the this our will Skyline Market, Medical I TumorGenesis the the Helomics

a auditor. our & auditor. Subsequent we four independent a Deloitte accounting quarter-end independent welcomed Touche, First as big on update to firm, quick our the

underway Given changes us can it the expands. company the major workload the that as to are important our the at of increase auditors for scope was in handle that have business

and commitment We evolves. as practices, of the pleased strong procedures best have believe passed and reflective strict governance very are company appointment to Deloitte's our to is very acceptance a this corporate

Therapeutics is physicians market is plans Now defined around end on better to an to the the expected Zion according as major are operating our developed for personalized cancer for moving to of care the increasingly the within to opportunity a position as to $XXX billion cancer global by oncology. oncology the to establish targeted growth life targeted Market responses of market to invaluable Research, predict by generate companies as drug, in enabling field revenues cancer. presents of and company sciences of leading molecularly changing precision options emergence patients. The of medicine strategic Precision The precision face treatment the of leader resource to precision this the to treatment XXXX therapies

cancer. approach powerful entry quarter TumorGenesis of made on into we transitional TumorGenesis Helomics and first formation our formed was progress, focus a investment tumors in in cancer our market company a growing rapid initial The pioneer new XXXX as the laboratory, of Corporation. the to for subsidiary with time with to ovarian was XX% this our an accelerating

would has President including team functions joins strong Vice machine executive and of Strategy. of Collins us generation recap from where far roles serving already Incorporated. informatics the TumorGenesis external licenses business TumorGenesis. to as our to to development We of entrepreneurial a securing discovery, appointing next He ahead? bioinformatics drive several his advance Mark strategy, has Helomics variety a so discovery and both the Helomics. collaborative in call in between Mark President he's global to in startup multiple this companies Dr. models technology of Therapeutics the has we what been lead software turn from will board as member record and within now held of Innovation In learning at enhance I a the a since to three several we have drug put consultant TumorGenesis out and to and Richard together appointment the the and team and the the founded if have space. a relationship go and pharma progress made, serve for we threat company strategy great to business Precision TumorGenesis expect He lay Richard proven and setting engaged the strategy like over Gabriel please next the XXXX. the against can Richard development, Richard addition is to over as see you would a to including, for months. PDX executing TumorGenesis tumor development track instrumental public

Richard Gabriel

Yeah, to to I'm thank be Carl. you here talk pleased TumorGenesis. today about

it drugs. keen drug using lower funded the tumors and away mouse new a patient-derived and screening its has mouse cell has pharmaceutical robust This model companies model, many samples developers. It standard drugs tumors the developing model to as advanced and other opportunity, that screen The shift cancer tissue patient-derived on laboratory. to new is is PDX the only a National to TumorGenesis from toward to model, Institute mentioned the evaluating economic patient-derived more Cancer The the traditional presents and abandoned cost mouse and technology, as Carl PDX technologies screen the a researchers. in offers new lines for to institutions searching is approach major or NCI is samples there As growing more new as alternatives mouse PDX the for is standard and technology,

or by cell annual for is states three Organization culture is that for CRO the CAGR top Research services needs mouse show dimensional and studies industry of NCI The drug XXXX. Research faster, goal compounded expected the kits the the discovery growth for year. is select BCC cell cheaper, potential to the and best this to or for a Recent expected of samples than Our per culture with of non-human services million XXXX. dollars physicians combinations exceed that to by of top XX% helping expected Clinical market $XXX and million categorize model. solution $XXX to meet tumor the rate several treatments patient-derived technologies sector is the the accurate billion more assay is PDX

for of Our initial on half ovarian these first TumorGenesis there Currently in XXXX. the of focus completing ovarian mutations each cancer will and on be cancer. mutations are focused of tumor generation is XX

into thinking cancer body the for a if Each cancer The enable drugs grow which We more will and in the cells particular relevant our TumorGenesis the Ovarian of as strategy. also personalized enable licenses pancreatic, hold in of model PDX will can thereby mutations long-term cells determine then by woman's will into companies will their place these that TumorGenesis exclusive to also the systems test how tumors therapy fool may with still to turn drugs. nothing Helomics, tumors for patient of brain provide will designed developers cancer way are expansion evading wrong, were drugs new approach to system body. which tumor patient cells -- lung, testing closely in and many characteristics. a fool produce brain for different the in drive cancers chemotherapies. immune the display to This model for breast, cancer they development -- Testing patients patient's in of behaving pharmaceutical immune is respond system colon, different the collaboration take which mimics response. and

first to stage TumorGenesis In the who these efforts, expect in announcing the Once Stage to tumor growth, development, two, milestones the a the fourth we with contracts of commercial the tumor. of completed aim four six be quarter quarter be can cancer in are establish over We to We to technologies structure validate have the cancer parallel expect been characteristics This These This pathologists, a discovering explore when secure our of in mimic will to companies involves to the securing with oncologists quarter can sometime is models. reached. our approach. following the pharma quickly tumor. one, commercialization the first in our next three are weeks. we to Once adopters Stage commence we by completed ovarian these our cancer of actions. with setting growing clinical tumor are the we these seeking of This peptide moving XXXX. estimated sequence. we keep grown Step is pay samples to our patients. peptide would to samples externally tumors four time with help mutation. the new our third closely enter early course and exciting XXXX. of taking pipelines, the which we have patient’s as sometime the for three, for optimizing fourth and stages, TumorGenesis first shareholders to strategy. to apprised end them and aim companies at will This be selecting first and very these

Carl. Carl? turn will to Now I it back

Carl Schwartz

about its years of the the in market. us complement drug precision which We relationship Richard. response XXX,XXX purchase we over when strategy space you, the clinical actionable therapies. effectiveness and and new Helomics market cement data in treated ownership an and advanced tumors. model Helomics clinical very and at Thank the the has the TumorGenesis revolutionize technology to excited completed patients of in body positively most a has our for to business is oncology will edge about our combining the LOI going development our Testing will Subsequent grow the of what the we part with growth stake for oncology. to an Helomics Helomics. believe will cancer that now to Vardzel, Helomics kind contains remaining equity Precision Gerry roadmap therapy and personalized total This this assets of complete trials in in of signed are I'll the bring is monetize the cells the oncologists been and the personalized XX% of database, potential profiles give patient's impacting revenues Gerry developed our offer TumorGenesis of growth turn XX [ph]. CEO quarter Acquiring to to patient tumor they're lab tumor full Helomics. past and transaction are with forms precision truly before advance data has and our Together over offering a you important over their the these testing. in sets artificial a our of testing provides outcome. and been cancer to of the to XXX%. to data to drug clinical to To call intelligence opportunity competitive With Therapeutic. quarter guide end [ph] This deepening talk oncology patient unique offering, enhance This doing expectations over the one

Gerry Vardzel

Both valuable and this today which molecular generate revenues respond and to you model of and strong currently to various provide validation Thank in of our highly complementary targeted an the with sums to big rich trials paying actionable we cancer, update on making rapidly place. of areas business our of drugs, generating for companies here strategies immuno-oncology in Helomics be to recap To drive companies pillars, different patient demand you think substantial and Carl. There selection for on form those for from familiar, high business. business their who realize growth such to a discovery It's have repurposing. diagnostic, are have increasing diseases, revenue company. companion are terms the for to patients of and all access that is data. investors progress a the chemotherapy. is drug shown appetite significant asset Helomics in especially not in pleasure each biomarker position an data in patients pharma we pharma three with cancer tumors are the data of Helomics the how on has details a asset to

diagnostics biotech This lab new state-of-the-art to clinical during drive integrated to business. to and the the our first, pharma, provide companies development trials. leverages services The CLIA specialty and diagnostic of clinical therapy CRO

companies, We have with contracts pharmaceutical and formed grow revenues. to diagnostic, biotech

an in more early and increasing several While potential trend services more is in this as signed area the the for this industry ramp, trials. of have and the Precision we and dollar its business more growth currently multiple matures market projects stages and CRO the has and work. is our clinical and have of high division multibillion Therapeutics

selection bioinformatics; trial. part currently dChip that a use comprehensive Helomics recruitment to significant disease has pilot from trials from of annual specimens data the The the a Revenues and clinical volume this drive CRO provides $XX,XXX generates researchers This mine patient powered in as its for diagnostic key bank. over for turn XX $XXX,XXX companies to insight we drive to partnership from has dChip engine rich more our is a development, for rising, business. XXX,XXX the or Pharma an tumors very drug second for that from intelligence up study, to CRO tumor The data bioinformatics the clinical depth patient for allowing services, range is $XXX,XXX initiatives. additional of and years data study platform generate proprietary part Helomics biomarker dChip produce elements. to continuously discovery which testing. simple that a selection tumor insight diagnosis for repurposing actionable artificial patient diagnostic this clinical this a clinical subscription and knowledge revenue. base that dChip $XXX,XXX and aid to collects integrated potential of or to over is profile in actionable involves of will a the generated

end increase of are currently XX this year. a three week the the are working specimens per securing by week We to number tumor to and

market As relatively ramp modest breakeven bring are significant investment base has rapidly accelerate already collaborations Helomics knowledge collection. target over see able we kind Precision since to our key strategic data to negotiating cancer. be expect this revenues grow will to the this for invested and return that process, are the in and several in third and with on towards we To $XXX quarter. we on investment Therapeutics ovarian enrich the a to million dChip dChip was

power The and comprehensive the third, our intelligence a oncology this of involves personalized insights, to for roadmap our using oncology dChip patients the artificial their precision profile oncologists. provide tumor and

efforts and received past we and significantly have over months outreach pleased have ramped oncologists our approach. the feedback several are validation to oncology positive insights precision Our for to

insights we increasing the intangible assets execute We strategy. to with are working medical also centers precision as revenues. around company to generate academic for form on the additional deals oncology to These world this create value strategic will

leaders those provide can from While data and selection approach applying this the System. we breast, we therapy. call We an the tumor XX profiles we're the now providing tests. and We're cancers our segment in chemo the of the believe intelligence for update the in most treatment specialized precision specifically precision focus. of that With world the space other the the for us of specific us data make will to What other library artificial biomarker has running that, intelligence turn intend insights industry. Carl, years artificial he sales attendant over in be Furthermore, effect this the and to XXX,XXX the data the assay to cancers in development not to its oncology will so of world kind molecular space, over market cancer. obtained in differentiates the of already can go Helomics our back provider our of on leader STREAMWAY one companies believe I in six six six unlike the lung only that cancers, company actionable pancreatic, we the the in targeting; ovarian, we oncology can of is are colon, be the brain for facilitate

Carl Schwartz

Thank you Gerry.

sales Division the of STREAMWAY first evidenced with by to as Skyline XX growth by revenue the gain driven Our the of fiscal was momentum XXX% XXXX. reaching strong in $XXX,XXX the three Medical the This in Systems quarter continues first of compared quarter. sale

XXX Systems lead to sales To-date has that based Our were sales incremental four to include improved Minnesota-based our Virginia sales presence Hospital U.S. revenues new higher customers have unit and the of system. force customers sales Health expanded U.S. are sold from the prominent a STREAMWAY accelerate were result we and key our ramping hospital some which to our Intermountain customers in and sales marketing of the and efforts, Flagship we top conferences. our University the at To strategy and industry increasing secure hospitals as such Utah. new of to our

radiology majority in are current While exploring several QX conferences the [ph] large quarter on Within among to grow center is these of today medical where is large already for The in most the typically field. this XXXX liver for and participated the volume have volume due within referring is the market STREAMWAY revenue. key time sales a industry immediate and paracentesis this the events the our is constantly have been interventional decision and focus opportunities at procedures new there profile the to performed of we System raise the transplant makers facilities. we in believe, facility main our slow to of opportunity

we to addition surgery, sales. believe include targets present to to success and expand promising other into to wide cystoscopy a IR aim securing us grow sales urology for rooms, which leverage opportunity These a departments we deep endoscopy In and approach. using our

first up by strategy key element John International Rasschaert. Sales, to of headquarters, President of international markets during opened is Vice European key our quarter, Paul our sales our new the Another penetrate we and headed

and Germany, Sales have We over region. experience Benelux the the in and with distributors Germany XX UK, Spain, independent Portugal negotiations also Director of underway hired with years' France, a in

several hospital the the STREAMWAY on the we and will market in market make the half in footprint. sales about during we're we our in with chains team early have the half this progress ongoing we meaningful opportunity secure generated international and first expect over is the of made, the clinics second our expect unique that medical invest interest a and XXXX. Based that pleased While the untapped And past underway sales are of System. to in its in our with extremely discussions major this we of in the to second benefits educating STREAMWAY to based to continue has days, Europe sales market XXXX. European months, Europe Europe exciting grow

more the results to Now quarter in I’ll discuss Bob, detail. ahead. financial go for Meyers, over call to please the turn Bob our

Bob Myers

Thank $XXX,XXX you, XXXX, compared was $XXX,XXX ended quarter for with quarter for filed which the XX, compared during the XX afternoon. fiscal results our sold turn quarter XX, of March March Revenue XXXX. financial earlier quarter first now for we with system Carl. with systems sales the the to ended the fiscal XXXX STREAMWAY three I STREAMWAY XXXX. will SEC ended quarter the this XX, in We first March

in As gain the system year. remainder Carl months we ramp sales XXXX. first the the mentioned, traction of throughout campaign are STREAMWAY will to pleased system in up we believe three that witnessed our sales and STREAMWAY the the of have And marketing we continue with for

was increased with of half profit XX, X.X quarter as average the due Gross in of March period addition The approximately due same per of with $X.XX which cash in profit The of a March million year. at XXXX $X conferences. available XX.X% weighted XXXX. this to X gross campaigns increase ended marketable marketing equivalents Gross of compared and and December decrease filters XX, compares million or million million year. due participation reps expect secure The XXXX. ended ended of common from $X.X revenues were for the cleaning XXXX for expenses with million in XXXX. drive higher our to XXXX This disposable XXXX of reported for shares ended per $X.X common of with was usage March net to million and revenue the million of profit the increased products, the as customers, continues primarily $XXX,XXX the company and March average compared $XXX,XXX to in the Europe to and had revenues. turn Our XX, shareholders offering cash March latter million XX, to the generating was recurring awareness to we allotment the XX, sales XX.X of use securities improve available compared to sales points was now existing public the loss of Total open expenses prior back XXXX $X.X outstanding. Furthermore, among margin $XXX,XXX, first to cash, compared for the the $X.X line the increased or quarter $X.X increase over that, With This $X.X I XX.X% basis shares underwriter. quarter in to operating for -- revenue, XX, with the share exercised from proceeds net medical loss XX% questions. option a weighted million for by net the on outstanding. operator share quarter call shareholders to March on of

Operator

Thank take you. We’ll question Dana our from Allen. [Operator Instructions] first

Dana Allen

one calls the most That's interesting of hello. Q I've heard. Yes, ever

may in have on was So [ph] $XXX I think invested several, question invested say official Did I research that that Helomics it database? I think million numbers, you I the do -- I did answered. some $XX have it. I thought I been million in my my hear already saw have but first

Gerry Vardzel

is Vardzel, million been this invested has $XXX Gerry the years, good question, over the over Yeah, company. in

Dana Allen

saw I million months Okay. last about I true? or previous that in place the that $X annual that thought in some XX year whatever had And outs is sales

Bob Myers

in is we first the that released deal and with the amount where a answer on an a in like ownership party to individual. million CFO. to have article Helomics that the of them I'd stock that. third That $X was million is in true. is Bob is have we our the Myers This be really is to was escrow by That not earned. will first regarding included that alluded $X written XX%

Dana Allen

And revenue Helomics? good. currently Okay at there is

Bob Myers

is. there Yes

Dana Allen

year a much how Approximately it? is

Bob Myers

time, in We're this not prepared sorry. at to answer I'm point amount the

Dana Allen

for something is by the third whole breakeven possibly will for just by Helomics presentation heard Richard about I And you the said you the be was Okay. that particular that that -- about? quarter, that the talked thing I or achieved think in

Carl Schwartz

answer Gerry, me. let do you that or want to

Gerry Vardzel

You can answer it.

Carl Schwartz

that We the specifically they were approach quarter with will talking third breakeven. about Helomics

Dana Allen

That's at impressive. the is And what Helomics? headcount

Carl Schwartz

XX.

Dana Allen

XX the being thing amazing able do or growing Is there ahead to tumor there out okay. of this? opportunity. And that's anyone like you sounds

Richard Gabriel

there that's is This combined -- there them doing we approach. separate anyone we'll mean that that not be, of existing team is Richard merged existing the I'm this We Gabriel. found, merge are aware in I of aware -- that that with could don’t as actually in a technologies And licensed anyone and with think Helomics not anyone. technologies. -- the I'm tumor I has done there that. but three

Dana Allen

So there. it to out pretty nobody stuff, chance you're buy looking good sounds like that is so out the there

So or get you grow it the that's do is who's does that this obviously the outside tumor to sick, cloning inside someone how how body?

Richard Gabriel

It's of is a there glycoproteins complicated what's other and and very what's bad. a -- forth peptides good, environment. to markers, series the cells back and a in body, Well of signal variety

the the where years, not narrowed the the tumor included as have the cells group have idea, cancer is a oncology we've we survive. over to learned that over have developers cancer the We to only a cells preserve that's NCI that such environment. years down good of What

But well that structure support licensed in of which technologies working the as on hard. a we're it combination systems really in we would use as combination. the So be peptides, essence

Dana Allen

is dChip? the the on software. and thing, is that IC dChip or that Okay What in literally is

Carl Schwartz

data, learning response which data plus response of a system on is from out that built drug and we've tumors our molecular machine drug mostly XXX,XXX our It's data. using differentiator

Dana Allen

a that So dChip chip, probably term it's system an software really it's but correct? actually not that the hardware, is runs is IC used on

Carl Schwartz

in It’s it’s essence. software,

Dana Allen

Yeah. Yeah.

then so you. in $XX,XXXX software trying each, divide sounds been correct? the that sold, numbers is sell about revenue approximately interested they the STREAMWAY Got just it good. out And in Okay. the to industry, I've that, for by like on

Bob Myers

That's correct.

Our $XX,XXX. price is list

Dana Allen

Okay.

So -- Europe, annual positive? guess. And of sounds good you what to cash more even that's XXX do annual be in what rate that how that, get like is will you on many are count this sales, year, you think a flow it pretty necessary for unit division expecting you

Bob Myers

that at I rate. revenue amount unfortunately add point We out of end. two-thirds you that reaching have our income we on that of units would on am we we revenue not a this changes for prepared an that, that answer And did of Ideally, means there receive the lowers a give disposable exponential at the time. it disposables. breakeven in be to our amount to to

kind dynamic, a this on of that’s to So just difficult it’s little call. into go

Dana Allen

neighborhood. And right. cap, I something it's your think $XX the buying in $XX other or maybe your before million $XX million, thing, like million All so Helomics, market was that

we For way? see me of a or tumor opportunity, alone, sounds the growing your like big for of the thing revenue. sounds do level of your be you that excitement million company Tell terms have, same in potential, it it if like I'm potentially just this could like $XXX very crazy it something but

Carl Schwartz

I do.

Dana Allen

market tiny Okay, today? do how cap how explain you your is

Bob Myers

is market that I transition. think our in share

a market, we We have that now way move into are that our everything turn device have the STREAMWAY right this and on medicine system. that made well as stuck as of had that have Systems. Precision increasing and towards Medicine precision over is this of number with to investors the medical that years gearing we course STREAMWAY are our And we realized

we of investor. the So attracted and biomed pharma yet haven’t type

which Helomics happens near. the once acquisition, see should occurs. very, think very think is market waiting the I positive that they're in with that result see a we I hopefully to what And

Dana Allen

this a would whatever this or most producing way because [ph] interesting or is to -- that I've so by to, going the extremely of rare. suggest it sounds And of It that whatever slideshow seems taking call you ever in Yeah. conference something and along to go potential. call it I or have terms maybe conference the listened article a

guys on a congratulation together presentation. So putting great

Carl Schwartz

Thank you.

Dana Allen

That’s it me. from

Operator

to Rob [ph] Medical. next go of will Dove We Instructions] [Operator Skyline

Unidentified Speaker

Skyline. not On quarter the any we I I system the in third it quarter, [ph] is. own with have guys. software, in what am that's sold Hey STREAMWAY this the second did yet? XX we

Bob Myers

be to am the I have. the second the quarter. we at quarter approaching had end in looking Yes, the number first we of

Unidentified Speaker

Are Good. head. for remember the top on in about of target total XXX, still XXX just off year the for States, if my whole United the Okay. I don’t it’s the we or

Carl Schwartz

and on XXX, target. are we yes,

Unidentified Speaker

Okay. And with the Europe, [indiscernible].

Carl Schwartz

Oh, yes sir.

Unidentified Speaker

Okay. about And the $X,XXX When be to is XX at supposed thing ]in completed? saw bid. [indiscernible] XX:XX:XX NASDAQ, the the Helomics last your acquisition May the IDX: Thu XXXX news [Author I

Bob Myers

but under being now continuous XX not days price issuing NASDAQ Right we $X. danger of any in letter us under $X of that we are are takes bid

$X of that that stages early the So and we then would on a defined the of gone agreement times. over Helomics couple of that the Certainly change as are well. that we we as merger close a have hope merger

expect We shortly. that merger very, close to very

may hear certainly. week within that the You

Unidentified Analyst

That sounds really good.

have Appreciate it. I That think been me. does that for [indiscernible] answered it.

Carl Schwartz

Thank you.

Operator

Instructions]. no to any queue, additional questions like call over Schwartz Carl remarks. the or With back the I'd turn further to [Operator in with closing

Carl Schwartz

Thank you operator.

like Precision By to how on to the a company value. to a Therapeutics' play phase Before this real to technology treatment. partner we medicine. and the major era transformational under growth I'd life and future enable we can the leverage incredibly as are and the We're a healthcare There about innovation, of outcome growth will cancer and revolution make on build have roof Oncology opportunity impact us. reiterate major believe role Precision as an patient's this industry our we positioning call. us to to shareholder focusing excited new the develop accelerate together a advanced enter opportunity excited as is targeted, we before drive opportunity we closing today's believe entry underway personalized by one we into our sciences' integral bringing most about

created model here. very we For the to you for investors, have important understand it's

complementary Oncology Furthermore growth we're for across revenues in Likewise generate generates generate Division which tumors, sale Precision only Insights direct, client grown producing. rapidly start donations, one driving it direct revenue intangible business Helomics revenues Helomics. while company. responsible assessment of the generates momentum upon and our synergies of the business it where sales in Our monetize virtual turn from asset to not Insights aims at TumorGenesis that drives stream offering to grow revenue tumor business also on The revenue of base, point between bring of another is that the Oncology areas build are individual TumorGenesis Helomics' advantage all commercial testing and the areas tumor. already which also we now interconnected take three at a to and base can by biobank. it's lab our Oncology division

the ovarian, forward fuel will lung, our to close now I Medicine ascent become I you once look pancreatic QX colon, company updating that and six Precision in call. areas; leading stack to Of joined for biobank, in core upon breast, call. Thank course who you the revenue again specimens business each on in cancer. raising focus say, stack Thank to our on believe everyone a drive brain you. We the each near streams Precision the various valuation value whole. other this add other of model I which shareholder even tumor the Therapeutics and this more us. With will again will our -- should up against And the ultimately the term

Operator

does you This your We for conference. today's conclude participation. thank

You may now disconnect.

Predictive Oncology (POAI) 15 May 182018 Q1 Earnings call transcript